Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions
Smoking CessationTobacco Use Cessation
Interventions
BIOLOGICAL

NicVAX

100 μg, Formulation A, on Days 0, 21, 42, 91 \& 182

BIOLOGICAL

NicVAX

200 μg, Formulation A, on Days 0, 21, 42, 91 \& 182

BIOLOGICAL

NicVAX

200 μg, Formulation B, on Days 0, 21, 42m 91 \& 182

BIOLOGICAL

NicVAX

300 μg, Formulation B, on Days 0, 21, 42, 91 \& 182

BIOLOGICAL

NicVAX

400 μg, Formulation B, on Days 0, 21, 42, 91 \& 182

Trial Locations (1)

6229 HA

University of Maastricht, Maastricht

Sponsors
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Nabi Biopharmaceuticals

INDUSTRY

NCT00218413 - Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals | Biotech Hunter | Biotech Hunter